CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
Rattachement africain : de, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We phenotypically and functionally analyzed blood samples from 46 patients focusing on CD16+ NK cells, CD16+ T cells and CD16+ monocytes. Kaplan-Meier survival curves show a superior progression-free survival (PFS) for patients having more than 1.6% CD16+ T cells (p = 0.02; HR = 0.13 (0.007–0.67)) but an inferior PFS having more than 10.0% CD16+ monocytes (p = 0.0003; HR = 16.0 (3.1-291.9)) at diagnosis. Surprisingly, no correlation with NK cells was found. The increased risk of relapse in the presence of > 10.0% CD16+ monocytes is reversed by the simultaneous occurrence of > 1.6% CD16+ T cells. The unexpectedly strong protective function of CD16+ T cells could be explained by their high antibody-dependent cellular cytotoxicity as quantified by real-time killing assays and single-cell imaging. The combined analysis of CD16+ monocytes (> 10%) and CD16+ T cells (< 1.6%) provided a strong model with a Harrell’s C index of 0.80 and a very strong power of 0.996 even with our sample size of 46 patients. CD16 assessment in the initial blood analysis is thus a precise marker for early relapse prediction. High CD16+ T cell counts have a positive correlation with PFS in aggressive NHL/DLBCL patients (p = 0.02; HR = 0.13, 0.01–0.7). High CD16+ monocyte counts have a negative correlation with PFS in aggressive NHL/DLBCL patients (p = 0.0003; HR = 16.0, 3-292). The combined assessment of CD16+ T cells and CD16+ monocytes accurately predicts PFS in aggressive NHL/DLBCL patients. The strong protective function of CD16+ T cells could be explained by their high antibody-dependent cellular cytotoxicity.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients
- Date Crossref
- 28/09/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Saarland University Department of Medical Biometry pays non établi dans la noticeUniversité ou école supérieure
-
Zimmer Biomet (Netherlands) pays non établi dans la noticeEntreprise
-
Goethe University Frankfurt Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
Frankfurt Cancer Institute pays non établi dans la noticeOrganisation à but non lucratif
-
German Cancer Research Center German Cancer Consortium (DKTK) pays non établi dans la noticeStructure de recherche
-
Heidelberg University pays non établi dans la noticeUniversité ou école supérieure
-
Technische Universität Darmstadt pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Center for Integrative Physiology and Molecular Medicine (CIPMM) pays non établi dans la noticeUniversité ou école supérieure
-
Technical University of Darmstadt Institute for Organic Chemistry and Biochemistry pays non établi dans la noticeUniversité ou école supérieure
Department of Medical Biometry — Saarland University, Zimmer Biomet (Netherlands) et Department of Pediatrics — Goethe University Frankfurt, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.